256 related articles for article (PubMed ID: 31222012)
21. Detection of
Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
[TBL] [Abstract][Full Text] [Related]
22. Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.
Kidess-Sigal E; Liu HE; Triboulet MM; Che J; Ramani VC; Visser BC; Poultsides GA; Longacre TA; Marziali A; Vysotskaia V; Wiggin M; Heirich K; Hanft V; Keilholz U; Tinhofer I; Norton JA; Lee M; Sollier-Christen E; Jeffrey SS
Oncotarget; 2016 Dec; 7(51):85349-85364. PubMed ID: 27863403
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of KRAS, NRAS and BRAF hotspot mutations detection for patients with metastatic colorectal cancer using direct DNA pipetting in a fully-automated platform and Next-Generation Sequencing for laboratory workflow optimisation.
Gilson P; Franczak C; Dubouis L; Husson M; Rouyer M; Demange J; Perceau M; Leroux A; Merlin JL; Harlé A
PLoS One; 2019; 14(7):e0219204. PubMed ID: 31265477
[TBL] [Abstract][Full Text] [Related]
24. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
25. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
[TBL] [Abstract][Full Text] [Related]
26. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
27. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
[TBL] [Abstract][Full Text] [Related]
29. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
30. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
[TBL] [Abstract][Full Text] [Related]
31. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
[No Abstract] [Full Text] [Related]
32. Clinical performance evaluation of a sensitive, rapid low-throughput test for KRAS mutation analysis using formalin-fixed, paraffin-embedded tissue samples.
Weyn C; Van Raemdonck S; Dendooven R; Maes V; Zwaenepoel K; Lambin S; Pauwels P
BMC Cancer; 2017 Feb; 17(1):139. PubMed ID: 28201998
[TBL] [Abstract][Full Text] [Related]
33. KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer.
Xu JM; Liu XJ; Ge FJ; Lin L; Wang Y; Sharma MR; Liu ZY; Tommasi S; Paradiso A
J Exp Clin Cancer Res; 2014 Dec; 33(1):104. PubMed ID: 25491325
[TBL] [Abstract][Full Text] [Related]
34. Analysis of KRAS, NRAS and BRAF mutational profile by combination of in-tube hybridization and universal tag-microarray in tumor tissue and plasma of colorectal cancer patients.
Damin F; Galbiati S; Soriani N; Burgio V; Ronzoni M; Ferrari M; Chiari M
PLoS One; 2018; 13(12):e0207876. PubMed ID: 30562355
[TBL] [Abstract][Full Text] [Related]
35. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancer.
Schlick K; Markus S; Huemer F; Ratzinger L; Zaborsky N; Clemens H; Neureiter D; Neumayer B; Beate AS; Florian S; Martin V; Grundbichler M; Weiss L; Melchardt T; Greil R; Egle A
Pancreatology; 2021 Dec; 21(8):1466-1471. PubMed ID: 34511398
[TBL] [Abstract][Full Text] [Related]
37. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
[TBL] [Abstract][Full Text] [Related]
38. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib.
Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM
Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802
[TBL] [Abstract][Full Text] [Related]
39. Enrichment technique to allow early detection and monitor emergence of KRAS mutation in response to treatment.
Kitagawa Y; Okumura K; Watanabe T; Tsukamoto K; Kitano S; Nankinzan R; Suzuki T; Hara T; Soda H; Denda T; Yamaguchi T; Nagase H
Sci Rep; 2019 Aug; 9(1):11346. PubMed ID: 31383871
[TBL] [Abstract][Full Text] [Related]
40. Utility of KRAS mutation detection using circulating cell-free DNA from patients with colorectal cancer.
Yamada T; Iwai T; Takahashi G; Kan H; Koizumi M; Matsuda A; Shinji S; Yamagishi A; Yokoyama Y; Tatsuguchi A; Kawagoe T; Kitano S; Nakayama M; Matsumoto S; Uchida E
Cancer Sci; 2016 Jul; 107(7):936-43. PubMed ID: 27116474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
